PF-044

The identifier **PF-044** is a non-specific, truncated prefix or shorthand code name that refers to several distinct small molecule drug candidates developed by Pfizer. In scientific literature, 'PF-044' is most frequently used as an abbreviation for **PF-04418948**, a potent and selective prostaglandin EP2 receptor antagonist, or **PF-04457845**, a highly selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor. Additionally, the prefix is associated with other Pfizer pipeline assets, including **PF-04449913** (glasdegib), an FDA-approved Smoothened (SMO) receptor inhibitor used to treat acute myeloid leukemia (AML), and **PF-04494700** (azeliragon), an oral receptor for advanced glycation endproducts (RAGE) antagonist previously evaluated for Alzheimer's disease and diabetic nephropathy.